Original Article

SIRT3 protects endothelial cells from high glucose-induced cytotoxicity

Guodong Liu, Mingming Cao, Ying Xu, Yanbo Li

Department of Endocrine, The First Affiliated Hospital of Harbin Medical University, 23 Youzheng Str, Harbin 150001, P.R. China

Received November 11, 2014; Accepted December 24, 2014; Epub January 1, 2015; Published January 15, 2015

Abstract: Diabetes is a frequent and increasing public health problem with a large economic burden in modern society. Endothelial cells dysfunction was involved in the development of diabetes-associated diseases. Sirtuins are a conserved family of NAD-dependent deacetylases. However, the role of sirtuins in diabetes-associated endothelial cell dysfunction was relatively unknown. In this study, we focus on the intrinsic link between SIRT3, a mitochondrial sirtuin, and high glucose-induced endothelial cells dysfunction. We showed that loss of SIRT3 expression was associated with decreased viability in endothelial cells from diabetes patients. Knockdown of SIRT3 decreased viability of endothelia cells exposed to high glucose condition. Further, mechanistic study showed that SIRT3 repression results in SOD2 acetylation, leading to SOD2 inactivation, which enhanced high glucose-induced oxidative stress in endothelial cells. Our data suggested that SIRT3 protects endothelial cells from high glucose-induced cytotoxicity. Our findings are considered a significant step toward a better understanding of diabetes-associated vascular diseases.

Keywords: Diabetes, SIRT3, endothelial cell dysfunction, high glucose

Introduction

Diabetes is a frequent and increasing public health problem with a large economic burden in modern society. Hyperglycaemia, β-cell dysfunction and insulin resistance are the hallmark clinical manifestation of diabetes [1]. Diabetes is associated with an increased risk of multiple complications, including microvascular disorder, obesity and hypertension which may finally lead to cardiovascular disease [2]. Although cardiovascular diseases result in approximately 80% of diabetes-associated death [3], the mechanisms responsible for the development of diabetes-associated cardiovascular disease are still unclear.

Accumulating evidences had shed a light on the involvement of endothelial cells dysfunction in the development of diabetes-associated diseases. It was demonstrated the bioavailability of NO, a crucial short-lived molecule, is reduced in endothelial cells from diabetes patients, which is associated with disorder in vascular tone [4]. Further, using an Nrf2/antioxidant response element (ARE)-driven luciferase reporter gene assay, it was shown that the transcription activity of Nrf2 was enhanced under diabetic conditions. Additionally, high-fat diet-induced endothelial dysfunction was more severe in Nrf2−/− mice, as shown by the significantly diminished acetylcholine-induced relaxation of aorta of these animals compared with HFD-fed Nrf2+/+ mice [5]. It is also reported that expression of miR-503 in endothelial cells is upregulated under high glucose treatment and ischemia-associated starvation. Delivery of miR-503 inhibitor to the ischemic adductor of diabetic mice rescued diabetes mellitus-induced impairment of postischemic angiogenesis and blood flow recovery [6]. However, detailed illustration of the key factors in high glucose-induced cytotoxicity in endothelial cells was still needed.

Sirtuins are a conserved family of NAD-dependent ADP-ribosyltransferases and/or protein deacetylases involved in metabolism, stress response. The mammalian sirtuin family consists of seven sirtuins that are localized to the
SIRT3 and endothelial cell dysfunction

nucleus (SIRT1, SIRT6, and SIRT7), mitochondria (SIRT3, SIRT4, and SIRT5), and cytoplasm (SIRT2), respectively, and that regulate a wide range of intracellular processes [7]. Among them, SIRT3 is mainly localized in mitochondria and regulates several key oxidative pathways by targeting many enzymes involved in central metabolism. For instance, SIRT3 mediates deacetylation of complex I and complex II to activate electron transport [8]. SIRT3 also induces fatty acid oxidation during fasting in hepatocytes via deacetylation of LCAD [9]. Since morphological and functional changes in mitochondrial disrupt the endothelial physiological function [10], we proposed that SIRT3 may have a role in endothelial cell dysfunction in diabetes. In this study, we showed that SIRT3 expression was associated with decreased viability in endothelial cells from diabetes patients. Loss of SIRT3 expression enhanced high glucose-induced cytotoxicity. Further, mechanistic study showed that ROS production and SOD2 deacetylation was involved in SIRT3-mediated protection of endothelial cells.

Materials and methods

Clinical samples

The blood samples were obtained from diabetes patients and healthy donors at First Affiliated Hospital of Harbin Medical University. All participants gave written informed consent prior to sampling. A total of 12 ml blood sample was obtained from each diabetic patient or healthy donor. About 2 ml blood was used to determine the glucose concentration, and 10 ml blood sample was used for isolation of circulating endothelial cells.

Isolation of circulating endothelial cells

Human circulating endothelial cells (CD34+) were isolated from blood samples by using the MACS system (Miltenyi Biotec GmbH, Germany), as described previously [11, 12].

Cells culture

Human umbilical vein endothelial (HUVEC) cells were maintained in low glucose Dulbecco's modified Eagle's medium (DMEM; Gibco, USA) containing 5 mM glucose, 10% fetal calf serum (Gibco, USA), penicillin (100 U/L) and streptomycin (10 mg/L).

Immunoblot

Cell samples were harvested and lysed in lysis buffer (Beyotime, China). Samples were separated by SDS-PAGE and transferred to PVDF membranes (Amersham Biosciences). The membranes were blocked with PBS containing 0.1% Tween 20 and 5% skimmed milk at 37°C for 1 h and then probed by primary antibodies. The blots were probed with secondary antibody.
SIRT3 and endothelial cell dysfunction

Figure 2. HUVEC cells were transfected with siSIRT3 or siNC, and then treated with 30 mM glucose for 48 h. Cell proliferation was examined by MTT assay (A) and BrdU assay (B). Cell apoptosis was examined by TUNEL assay (C). HG, high glucose.

(diluted 1:10000; Santa Cruz Biotechnology) conjugated to horseradish peroxidase for 2 h at room temperature. Blots were visualized by enhanced chemiluminescence reagents (Cell signaling technology).

DCF staining

Endogenous ROS production was examined by staining cells with 2',7'-dichloro-fluorescein diacetate (DCFH-DA) (GENMED, GMS10016.2) according to the manufacturer’s instructions. The DCFH-DA signal was measured by Molecular Devices SPECTRAMAX M5 fluorimeter at 490 nm excitation and 530 nm emission.

Proliferation assay

MTT assay was performed using 96-well plate according to the manufacturer’s instructions. Cells were incubated with MTT (Sigma, St. Louis, MO) for 2 h, and then the insoluble sub-
stance dissolved in DMSO. The absorbance was read by multi-well spectrophotometer (MDC, Sunnyrale, CA) at 595 nm.

For BrdU labeling assay, cells were incubated with BrdU (Roche Applied Science, Indianapolis, IN) at final concentration at 10 mM for 4 h. BrdU signal was detected by using 5-Bromo-2'-deoxy-uridine Labeling and Detection Kit III (Roche) and read by multi-well spectrophotometer (MDC, Sunnyrale, CA) at 405 nm.

**TUNEL assay**

TUNEL staining was performed by using Dead End Fluorometric TUNEL system (Promega) following the manufacturer’s instruction. The TUNEL-positive cells were visualized and counted via fluorescence microscope (Zeiss, Germany).

**Metabolite assay**

The level of G16DP, citrate and succinate was measured by using PicoProbe™ Fructose-6-Phosphate Fluorometric Assay Kit, Succinate (Succinic Acid) Colorimetric Assay Kit and Citrate Colorimetric/Fluorometric Assay Kit, respectively, all of which were purchased from Biovision.

**Statistics analysis**

Differences between two groups were assessed by Student’s t test. Leaner regressions were tested by using the Spearman rank correlation. 

\* \( P < 0.05 \); \** \( P < 0.01 \); \*** \( P < 0.001 \).

---

**Results**

**Loss of SIRT3 expression was associated with decreased viability in endothelial cells from diabetes patients**

As an initial test, we determined the impact of high glucose condition on SIRT3 expression in endothelial cells. Circulating endothelial cells from diabetes patients and normal healthy donors were isolated, and the expression level of SIRT3 was examined by real time RT-PCR. As shown in **Figure 1A**, no apparent changes were found in SIRT3 expression in circulating endothelial cells from diabetes patients versus normal donors \( P = 0.97 \).

Interestingly, we found that, among the diabetic patients, the circulating endothelial cells harboring a low SIRT3 expression showed a decreased cell proliferation rate compared to those cells with high SIRT3 expression (**Figure 1B**). These results suggested that loss of SIRT3 expression was associated with decreased viability in endothelial cells from diabetic patients.

**SIRT3 protected endothelial cells from high glucose-induced cytotoxicity**

It was previously observed that exposure to diabetic mellitus causes endothelial cells dysfunction, even leading to cell death [13]. Thus we sought to determine if SIRT3 possessed a role in high glucose-induced cytotoxicity in endothelial cells. To this end, primary culture of human umbilical vein endothelial (HUVEC) cells was established. HUVEC cells were transfected with specific siRNA targeting SIRT3 (siSIRT3) or non-targeting siRNA (siNC), and then treated with 30 mM glucose.

To unveil whether SIRT3 was involved in high glucose-induced cytotoxicity in endothelial cells, proliferation and apoptosis in endothelial cells was examined. As shown, the proliferating cells were notably reduced upon SIRT3 knockdown, revealed by both MTT (3-(4,5-dimethyl-
SIRT3 and endothelial cell dysfunction

Figure 2A and Figure 2B. In MTT assay, the proliferation ratio in siSIRT3-treated cells was decreased by 55.6%, compared to siNC-treated cells (Figure 2A). Similarly, the BrdU signal decreased by 48.20% upon SIRT3 knockdown in BrdU incorporation assay (Figure 2B, *P < 0.01*). Further, loss of SIRT3 expression also increased apoptosis in endothelial cells under high glucose condition. As shown in Figure 2C, a significantly increased number of TUNEL-positive cells were found in siSIRT3-treated HUVEC cells (51.25±4.41), compared to siNC-treated cells (32.75±3.50, *P < 0.01*). Collectively, this data suggested that SIRT3 protected endothelial cells from high glucose-induced cytotoxicity.

Figure 4. HUVEC cells were pre-treated with 10 mM NAC for 4 h. HUVEC cells were then transfected with siSIRT3 or siNC, and treated with 30 mM glucose for 48 h. Cell proliferation was examined by MTT assay (A) and BrdU assay (B). Cell apoptosis was examined by TUNEL assay (C). HG, high glucose.

It was reported that diabetic mellitus could cause oxidative stress, which was implicated in high glucose-mediated cytotoxicity [14]. We thus asked whether SIRT3 had an impact on ROS production in high glucose-treated endothelial cell. To this goal, endogenous ROS production in HUVEC cells was examined by using 2',7'-dichloro-fluorescein diacetate (DCF) fluorescent probe. As shown in Figure 3A, loss of SIRT3 expression increased intracellular ROS level by approximately 2.5 folds, compared to control cells.

To determine whether SIRT3 rescued endothelial cell viability by regulating oxidative stress, a ROS inhibitor, NAC was used. As shown in Figure 4A-C, though knockdown of SIRT3 enhanced the high glucose-induced cytotoxicity, no apparent differences were found in either proliferation or apoptosis between siSIRT3- or siNC-treated cells when these cells were pre-treated with NAC. Therefore, these data suggested that SIRT3 protected endothelial cells by modulating high glucose-induced ROS production.

SIRT3 protected endothelial cells by modulating high glucose-induced ROS production

It is widely accepted that glycolysis and TAC cycle is the major source for cellular ROS production [15]. Further, SIRT3 plays a crucial role in regulating glycolysis and TAC cycle through modulating the key intermediates of these two metabolic pathways, including G16PD, citrate and succinate [8, 9]. To explore the potential mechanisms underlying SIRT3-mediated ROS inhibition, the level of G16PD, citrate and succinate were examined. As results, loss of SIRT3

SIRT3 regulates high glucose-induced oxidative stress by mediating SOD2 deacetylation

It is widely accepted that glycolysis and TAC cycle is the major source for cellular ROS production [15]. Further, SIRT3 plays a crucial role in regulating glycolysis and TAC cycle through modulating the key intermediates of these two metabolic pathways, including G16PD, citrate and succinate [8, 9]. To explore the potential mechanisms underlying SIRT3-mediated ROS inhibition, the level of G16PD, citrate and succinate were examined. As results, loss of SIRT3
SIRT3 and endothelial cell dysfunction

expression had no further impact on the level of these three intermediates (Figure 5A).

It is reported that SOD2 is an important ROS scavenger, and SIRT3 mediated SOD2 deacetylation at Lys68 which is an essential step of SOD2 activation [16]. Thus we have particular interests to examine the impact of SIRT3 on the acetylation status of SOD2. As shown in Figure 5B, 5C, treatment with 30 mM glucose reduced SOD2 acetylation and elevated SOD2 activity. However, high glucose-induced activation of SOD2 was markedly abolished by SIRT3 knockdown. These data suggested that SIRT3 regulates high glucose-induced oxidative stress by mediating SOD2 deacetylation.

Discussion

Endothelial cells dysfunction which was resulted from chronic exposure to various stressors, such as high glucose and oxidative stress was common in diabetes. Mitochondria are central to cellular metabolism, and dysregulation has been implicated in numerous diseases, including diabetes [17]. Understanding the regulation of mitochondrial enzymes and their associated pathways is essential to grasp how mitochondria function and adapt numerous metabolic processes and maintain cellular viability under the demands of diverse physical or pathological conditions [18].

Sirtuins are NAD-dependent deactylases that share homology to the yeast Sir2 protein. Their enzymatic activity is regulated by the ratio of NAD to NADH; high NAD levels activate sirtuins and conversely high NADH levels inhibit activity [19]. Of the three mitochondrial sirtuins, SIRT3 is the most studied to date and has been long been considered as a tumor suppressor. It is reported that siRNA-mediated knockdown of SIRT3 in colorectal cancer cell line augmented HIF-1α protein stabilization and transcriptional activity in hypoxic conditions, which results in a significant increase in cell proliferation and tumorigenic capability in xenograft models [20]. Further, knockout of SIRT3 in MEF induced chromosomal instability and decreased mitochondrial integrity. Though SIRT3 knockout MEFs could not immortalize, expression of a single oncogene (Myc or Ras) in SIRT3-deleted MEFs results in vitro transformation and altered intracellular metabolism [21]. Recently, accumulating evidences have linked SIRT3 to diabetes. It is shown that expression of SIRT3 was suppressed in pancreatic islets isolated from human type 2 diabetic patients, and knockdown of SIRT3 in mouse pancreatic beta cell resulted in lowered insulin secretion and increased beta cell apoptosis [22]. Moreover, apelin gene therapy increases myocardial vascular density and ameliorates diabetic

Figure 5. HUVEC cells were transfected with siSIRT3 or siNC, and then treated with 30 mM glucose for 48 h. Intracellular level of G16DP, citrate and succinate was examined by HPLC (A). Acetylation status of SOD2 was examined by immunoprecipitation followed by immunoblot; (B) SOD2 activity was determined by SOD2 activity assay kit. (C) HG, high glucose.
cardiomyopathy via upregulation of SIRT3 [23].

In present data, we investigated the intrinsic link between high glucose-associated endothelial dysfunction and SIRT3. We demonstrated that though the expression level of SIRT3 was almost unchanged in the circulating endothelial cells from diabetes patients, the endothelial cells with a low level of SIRT3 expression exhibit reduced cell viability in response to high glucose treatment, compared to those cells with a high SIRT3 expression. Further, knockdown of SIRT3 enhanced high glucose-induced proliferation inhibition and apoptosis in endothelial cells. Therefore, our data suggested a protective role of SIRT3 in endothelial cells against high glucose-induced cytotoxicity.

Oxidative stress has long been considered as important reasons for diabetic vascular complications [24]. In the present data, loss of SIRT3 expression enhanced high glucose-induced oxidative stress in endothelial cells. Further treatment with NAC reduced the intracellular ROS level, which in turn abolished SIRT3 knockdown-induced proliferation inhibition and apoptosis under high glucose treatment, suggesting that SIRT3 protects endothelial cell from high glucose stimulation probably through reducing intracellular ROS level.

Abnormal changes in glycolysis and mitochondrial metabolism were the major source for ROS production [14]. Aberrant accumulation of intracellular ROS could activate anti-oxidant proteins, including SOD2, which functions as ROS scavengers [25]. It is reported that, as a major mitochondrial deacetylase, SIRT3 reduced intracellular ROS level mainly by targeting either key metabolic enzymes or anti-oxidant proteins [9, 16]. In this study, we demonstrated that loss of SIRT3 expression markedly increased acetylation form of SOD2 in endothelial cells exposed to high glucose condition, which led to SOD2 inactivation, while repression of SIRT3 expression had no impact on the level of several metabolic intermediate products. Therefore, it is reasonable to infer that SIRT3 regulates high glucose-induced oxidative stress mainly by mediating SOD2 deacetylation, but not modulating the activity of metabolic enzymes.

Disclosure of conflict of interest

None.

Address correspondence to: Dr. Yanbo Li, Department of Endocrine, The First Affiliated Hospital of Harbin Medical University, 23 Youzheng Str, Harbin 150001, P.R. China. Tel: 86-451-53643869; E-mail: yanboliyb@126.com

References

SIRT3 and endothelial cell dysfunction